Chairman and Founder
Mr. Chen is the Managing Partner for Clearbridge Partners, an Asian venture capital firm. He is also the Managing Partner for Clearbridge Accelerator, a Singapore National Research Foundation (NRF) backed high-technology incubator and an investment committee member of Clearbridge BSA Pte Ltd.
Prior to founding Clearbridge, Mr. Chen worked at Pacific Century CyberWorks Limited, the incumbent and leading telecommunications company in Hong Kong. Mr. Chen is a member of the pioneering team at PCCW and was the President of CyberWorks Ventures, the Venture Capital and direct investment arm of PCCW. Mr. Chen was also the youngest member of PCCW’s Mergers Acquisitions executive committee, and was responsible for much of PCCW’s strategic expansion and many of its successful acquisitions and investments.
Mr. Chen has more than 12 years of entrepreneurship experience with start-ups, being the co-founder of 2 start-up companies with successful exits. Mr. Chen has also given talks on entrepreneurship in Hong Kong and the United States, including the Sloan School of Management at MIT. Mr. Chen is an active angel investor and was a member of the Hong Kong Science and Technology Park (HKSTP) incubator selection panel and a venture committee member of the Hong Kong Venture Capital and Private Equity Association (HKVCA). He is also currently a member of the Singapore NRF POC grant panel.
Mr. Chen is the recipient of the prestigious Sword of Honour from the Singapore Armed Forces, and holds a B.A., M.A. and M.Eng from the University of Cambridge, (U.K.).
Chee Wah CHONG
Director and Founder
Mr. Chong previously worked as a Communications Security Program Manager at the DSO National Laboratories. He won the prestigious KINETIC Award in DSO for his outstanding technical contributions to various initiatives in the defence sector. He oversaw various cryptographic and communication systems as well as direct research & development investments in excess of S$5 million annually. He was also the key technical decision maker on various national level projects.
Prior to working at DSO, Mr. Chong was with the Directorate of Research & Development (under the Defence Science & Technology Agency) as a Country Manager, where he was responsible for the long term strategic R&D plans for the Ministry of Defence. Mr Chong was also the Assistant Director of Finance Policy at the Ministry of Health (MOH) where his responsibilities included policy matters on Singapore’s key medical financial schemes.
Mr. Chong is the recipient of the Public Service Commission’s Local Merit Scholarship and has a B.Eng and M.Eng (Electrical Engineering) from the National University of Singapore.
Mr. Qian was the vice president, the director of public affairs and the secretary of the Board of Trauson Holdings Company Limited. Mr. Qian graduated from Simon Fraser University in Canada with both BBA and MBA degrees. He is now a registered senior economist. He serves as a member of Changzhou Municipal Chinese People’s Political Consultative Conference (CPPCC). Mr. Qian brings with him a wealth of experience in IPO and M&A, where he was responsible for project coordination and legal affairs, along with corporate re-organisation.
Joo Hock CHUA
Mr. Chua joined the former Singapore Technologies Group in 1987 where he was involved in the early phase of Singapore Technologies’ venture capital investments which became Vertex in 1988. Throughout his career in Vertex, he has been involved in investments globally particularly in the US, Singapore, Taiwan, China and Israel. He spent several years in the US from 1989 to 1992 and later from 1998 to 2004 where he was head of Vertex US office. Mr. Chua currently heads Vertex’s investment in India, Singapore, Korea and SE Asia.
Prior to Singapore Technologies Group, Mr. Chua was with the NatSteel Group where he was involved in venture capital investments and corporate project development activities. He worked in the Singapore Economic Development Board and the Singapore subsidiary of General Electric’s semiconductor division after graduating from the University of Singapore in 1979 with a Bachelor of Engineering (Mechanical). He also has a MBA from National University of Singapore.
Mr. Chua currently serves on the Board of muvee Technologies Pte Ltd, eGInnovations Pte Ltd, Reverse Logistic Co. Pvt Ltd, Anhui Bayi Chemical Co Ltd and Shandong Huaan New Materials Co Ltd. His past directorships include UTAC, Spreadtrum Communication, Silknet and others. He is also currently a member of both the Evaluation Panel for NRF POC Grant Scheme and the Advisory Board/Selection Committee of SMART Innovation Center.
Dr Juanita FU
Dr. Fu is a General Partner of Bioveda Capital, a venture capital firm focused exclusively on investments in healthcare and biotechnology.
She has more than ten years of clinical experience with a focus on internal medicine, and has practiced in the Singapore General Hospital, National University Hospital and in a group practice in the United States. She does investments through a family office in Kuo International Pte Ltd and is a director of Kuo Investments Ltd. In her own personal capacity, she does angel investments in early start-up companies.
Dr. Fu received her B.S. in Biology from Columbia University, New York and her M.D. from the University of Southern California. She is certified with the American Board of Internal Medicine and is also a registered physician with the Singapore Medical Council.
Nicolas H. ROELOFS, PhD
Dr. Roelofs served as Senior Vice President at Agilent Technologies Inc., as well as President of its Life Sciences Group from 2009 to 2013. He also served as the Vice President and General Manager of the Life Sciences division from 2006 to 2009. His contributions during his term at Agilent Technologies Inc., in the areas of business development, sales, manufacturing, R&D and marketing saw him play a key role in the life science business.
Prior to joining Agilent Technologies Inc., Dr. Roelofs was with Bio-Rad Laboratories, Inc., from 2005 to 2006 and served as the Life Science Group’s Group Operations Officer heading five business divisions spanning life science and food science. His time at Stratagene Corporation from 2001 to 2005 saw him serve as Senior Vice President of marketing, sales and business development for the first 2 years and as Chief Operating Officer for the last 2 years.
Professionally, Dr. Roelofs is a Global 50 Member and also a part of the Malaysian Biotechnology International Advisory Panel. He also serves on the Advisory Board of Chemical & Engineering News for the American Chemical Society Magazine from 2010 to 2013. Dr. Roelofs completed his M.S. in Organic Chemistry from Iowa State University following which he completed his PhD in Organic Chemistry from the University of Nevada, Reno.
Prof. Chwee Teck LIM
Advisor and Founder
Professor Lim currently holds joint appointments at both the Departments of Bioengineering and Mechanical Engineering at the National University of Singapore (NUS). He is also a Principal Investigator at the Mechanobiology Institute as well as a Faculty Fellow of the Singapore-MIT Alliance Center for Science & Technology. Professor Lim heads the Nano Biomechanics Lab which conducts basic and applied research in the mechanobiology of human diseases as well as the development of microfluidic biochips for the detection and diagnosis of cancer.
Prof. Lim has published more than 200 peer-reviewed journal papers (including over 30 invited/review articles and 12 ISI highly cited papers), 20 book chapters and delivered more than 200 plenary/keynote/invited talks. He is currently on the editorial boards of 11 international journals. Prof. Lim is also a Council Member of the World Council for Biomechanics. He has co-founded 3 start-ups that exploit inventions that he has developed in his lab.
Prof. Lim and his team have won several research awards and honors including the Wall Street Journal Asian Innovation Award (Gold) 2012, Credit Suisse Technopreneur of the Year Award 2012, TechVenture Most Disruptive Innovation Award 2012, Asian Entrepreneurship Award (First Prize) 2012, President’s Technology Award 2011, Faculty Research Award 2011, IES Prestigious Engineering Achievement Award 2010, Tan Kah Kee Young Inventor’s Award 2009, highly cited author award as well as Best Paper and Best Poster awards in international conferences. His research was cited by the MIT Technology Review magazine as one of the top ten emerging technologies of 2006 that will “have a significant impact on business, medicine or culture”.
Swee Jin TAN, PhD
Technical Advisor and Founder
Dr. Tan is one of the rising stars in the field of nanobiomechanics. He is the co-inventor for the Circulating Tumour Cell (CTC) Microfiltration BioChip – an innovative device which allows clinicians to isolate and enumerate circulating tumour cells from whole patient blood and, most impressively, retrieve wholly intact, viable circulating tumour cells. Dr. Tan is currently the Technical Advisor of Clearbridge Biomedics and the Technical Director of Clearbridge Accelerator.
Dr. Tan is a recipient of the A*STAR Graduate Scholarship which is awarded only to the top graduates in the fields of Biomedical Sciences, Physical Sciences and Engineering. He has also won several awards, including the Young Investigator Award at the 6th World Congress on Biomechanics and the prestigious Tan Kah Kee Young Inventors’ Award.
The author/co-author of several scientific publications, Dr. Tan has been invited to present his work at both local and international conferences, such as the International Conference on Biocomputation, Bioinformatics, and Biomedical Technologies and also at the prestigious National Institutes of Health (NIH), USA.
Dr. Tan holds a B.Eng (First Class Honours) and his PhD from the National University of Singapore.
Michael PAUMEN, PhD
Chief Executive Officer
Dr. Paumen, CEO of Clearbridge BioMedics held several senior leadership positions in the biotech and biomedical industries prior to joining the Company. Previously, Dr. Paumen was with Life Technologies – now Thermo Fisher Scientific and led commercial efforts in Next Generation Sequencing and Genomic Medicine in Japan and the Medical Sciences business for the Asia Pacific region. Highlights include achieving Medical Device status for the company’s sequencers and RT-PCR systems.
Prior to joining Life Technologies, he was CEO at Dx Assays Pte Ltd (Singapore), a developer of Molecular Diagnostics test systems for a period of 2 years. Before joining Dx Assays, Dr. Paumen was Technical Director at Affymetrix Inc. and developed their Sales and Marketing infrastructure in Japan.
Other earlier positions include a Scientific Affairs management role at QIAGEN GmBH, overseeing worldwide clinical collaborative studies in both academia and industry and the inception of QIAGEN’s first offices in Asia.
Dr. Paumen obtained his PhD from Johannes-Gutenberg University, Germany and researched on Programmed Cell Death at the German Cancer Research Centre and Kyoto University, Faculty of Medicine, Japan.
Ali Asgar BHAGAT, PhD
Chief Operating Officer
Dr. Bhagat received his MS (2006) and PhD (2009) in Electrical Engineering from the University of Cincinnati, USA. Following his degree he held Post-doctoral Associate position at Massachusetts Institute of Technology, USA prior to moving to Singapore. Before joining Clearbridge, Dr. Bhagat worked as a Research Scientist in the newly formed Biosystems and Micromechanics (BioSyM) group at the Singapore-MIT Alliance for Research and Technology (SMART) Centre, Singapore.
Author of over 10 peer-reviewed scientific publications, Dr. Bhagat’s research interests lies in developing microfluidics based solutions for efficient cell separation/isolation and applying them towards point-of-care disease diagnostics.
Senior Director, Strategic Development
Junquan leads design translation and product commercialisation for Clearbridge BioMedics. He directs product design, engineering and software development initiatives to meet both commercially-ready products and international regulatory standards, relevant to clinicians and pathology laboratories dedicated to cancer diagnostics.
He previously served as a Regulatory Specialist at Health Sciences Authority, consulting and training several medical technology companies seeking regulatory approvals in safety and performance of their medical devices. Prior to his regulatory role, serving in the A*Star Biomedical Research Council, he managed the establishment of Lonza’s cell therapy facility in Singapore. During his stint at St Vincent’s Institute in Melbourne, he led a team of researchers to successfully isolate islets and achieve the first human islet transplantation in Victoria, Australia.
Junquan graduated with Bachelors with First Class Honours in Immunology and Pharmacology from the University of Melbourne, Australia.
22-23 AUGUST 2017 | SEOUL, S.KOREA | PRESENTATION & BOOTH #3Learn More
NewsGenomeWeb Feature: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership to develop CTC CoRE in the U.S. PR Newswire: John Wayne Cancer Institute, and Clearbridge BioMedics announce partnership to develop Circulating Tumor Cell Centre of Research Excellence in the U.S. BioSpectrum: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership
22-23 AUGUST 2017 | SEOUL, S.KOREA | PRESENTATION & BOOTH #3Read more